On March 12, 2024, the China-Brazil Medical Innovation and Cooperation Forum, organized by AstraZeneca and jointly guided by the Shanghai Biomedicine Technology Development Center and the Shanghai Biomedicine Industry Promotion Center, was grandly held at AstraZeneca R&D China.
Dr. Chen Hongliang, Chairman of Xiamen Vangenes Biotech, was invited to participate in the forum’s featured roundtable session. Together with Mr. Marco Krieger, Vice President of Health Production and Innovation at FIOCRUZ (Oswaldo Cruz Foundation), Dr. Mauricio Medeiros, Chairman and CEO of the Institute of Immunobiological Technology of Latin America, as well as other members of the Brazilian visiting delegation and representatives of China’s government and enterprises in the healthcare industry, Dr. Chen conducted in-depth discussions and shared insights into opportunities for Chinese healthcare innovation to “go global” and expand cooperation with Brazil.
The successful holding of the China-Brazil Medical Innovation and Cooperation Forum will further deepen exchanges between China and Brazil in the field of healthcare, bringing more opportunities for substantial future cooperation in the industry. Xiamen Vangenes Biotech will be dedicated to comprehensively developing its business in Brazil across multiple fields, including non-invasive prenatal testing, non-invasive infant testing, and related consumables, actively promoting the widespread adoption of next-generation DNA sequencing technology in Brazil and delivering better, more cost-effective “Xiamen, China solutions” for the health and well-being of the Brazilian people.